ClinicalTrials.gg
CompletedNCT06264752MEnD-AKIUpdated Nov 10, 2026Results posted

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

An interventional study of Level A and Level B in Acute Kidney Injury, sponsored by University of Pittsburgh. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Prevention

How we know

Updated Nov 10, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Acute Kidney Injury by University of Pittsburgh — 2 open to participants now, 2 under way, none of them phase 3. Acute Kidney Injury · University of Pittsburgh.

Started
2024
the only one that year
No phase
6 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Acute Kidney Injury by University of Pittsburgh, this one is the only one that started in 2024, is one of 6 with no phase, and was the 9th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

2 of the 10 studies in Acute Kidney Injury by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Acute Kidney Injury by University of Pittsburgh, or all of them as a file.
02

Study summary

This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.

Read the detailed description

Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.

The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.

03

Conditions studied

  • Acute Kidney Injury

Keywords

  • acute kidney injury
  • drug-associated acute kidney injury
  • adverse drug event
  • pharmacist
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Physician-subject Inclusion

  • Physicians employed at UPMC hospital systems
  • Attending physicians of record who care for patients across multiple units outside ICU/ED
  • Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI

Physician-subject Exclusion

  • Physicians of record who only care for ICU or ED patients
  • Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients
  • Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.)

Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.

Patient-subject Inclusion

  • System alert identifying risk for AKI
  • Patient has attending physician who is participating in the randomized clusters
  • After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91

Patient-subject Exclusion

  • Patients with end stage renal disease on admission, baseline \<15, comfort measures only, or died before the intervention could be delivered
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
698 participants (actual)

Study arms

  • Experimental
    Protocolized stage-based intervention

    The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.

    Other: Level A · Other: Level B

  • Active comparator
    Usual Care

    A Cerner EMR-based AKI passive alert which is standard of care at UPMC.

    Other: Passive Alert

Interventions

  • OtherLevel A

    Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.

  • OtherLevel B

    The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.

  • OtherPassive Alert

    Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.

06

What researchers measure

Primary outcomes

  1. Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians

    Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so \~ 3000 patients were included for the per protocol analysis to be impactful.

    Time frame: up to 30 days

Secondary outcomes

  1. Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge

    Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.

    Time frame: up to 30 days

  2. AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3

    AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.

    Time frame: up to 30 days

  3. Nephrotoxic Burden

    Drug.days\* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. \*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.

    Time frame: up to 30 days

07

Results

Posted Nov 10, 2026
Limitations and caveats
The trial took place within UPMC hospitals that have already implemented some pharmacist-led nephrotoxin stewardship practices including renal dosing protocols, therapeutic drug monitoring, and pharmacokinetic services. Previous studies have shown that the EMR-based passive alert (usual care) improves patient outcomes compared to historical data with no passive alert. Implementing the MeND-AKI intervention in a health system without these existing strategies may result in a greater effect size.

Participant flow

Prospective physician subjects within the study hospital service sites were emailed an opportunity to opt out in October/November 2023. All physicians within the hospital service clusters who did not opt out were enrolled under waiver of consent at the the start of the study intervention on February 15, 2024.

Participant flow — Overall Study
MilestoneProtocolized Stage-based InterventionUsual Care
Started306392
Cluster randomized to usual care, physician received intervention05
Cluster randomized to intervention, physician received usual care40
Completed251229
Not completed55163
Withdrew: Physician never cared for a patient meeting alert or patient criterion; no intervention delivered.55163

Outcome measures

PrimaryNumber of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians

Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so \~ 3000 patients were included for the per protocol analysis to be impactful.

Time frame:
up to 30 days
Reported as:
Count of units · Patient encounters
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
Patient encountersProtocolized Stage-based InterventionUsual Care
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians1950899
Statistical analysis
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.711 · Odds ratio (or): 1.05 · 95% CI 0.82 to 1.35Binomial generalized linear mixed model
SecondaryNumber of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge

Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.

Time frame:
up to 30 days
Reported as:
Count of units · Patient encounters
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
Patient encountersProtocolized Stage-based InterventionUsual Care
No AKI to any Stage AKI15995
Stage 1 AKI to Stage 2+249112
Stage 2 AKI to Stage 314865
Statistical analysis
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.383 · Odds ratio (or): 0.89 · 95% CI 0.67 to 1.16Binomial generalized linear mixed model
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.089 · Odds ratio (or): 1.47 · 95% CI 0.94 to 2.28Binomial generalized linear mixed model
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.082 · Odds ratio (or): 1.41 · 95% CI 0.96 to 2.09Binomial generalized linear mixed model
SecondaryAKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3

AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.

Time frame:
up to 30 days
Reported as:
Least squares mean · days
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
daysProtocolized Stage-based InterventionUsual Care
AKI at any stage4.88 (3.94 to 6.02)4.96 (4.01 to 6.13)
Stage 1 AKI1.43 (1.01 to 2.03)1.48 (1.04 to 2.11)
Stage 2 AKI0.92 (0.55 to 1.55)0.73 (0.43 to 1.24)
Stage 3 AKI0.37 (0.15 to 0.93)0.21 (0.08 to 0.53)
Statistical analysis
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.817 · Incidence rate ratio (irr): 0.98 · 95% CI 0.86 to 1.12Negative binomial generalized linear mixed model
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.495 · Incidence rate ratio (irr): 0.97 · 95% CI 0.87 to 1.07Negative binomial generalized linear mixed model
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.004 · Incidence rate ratio (irr): 1.26 · 95% CI 1.08 to 1.47Negative binomial generalized linear mixed model
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.002 · Incidence rate ratio (irr): 1.80 · 95% CI 1.24 to 2.61Negative binomial generalized linear mixed model
SecondaryNephrotoxic Burden

Drug.days\* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. \*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.

Time frame:
up to 30 days
Reported as:
Least squares mean · drug days
Nephrotoxic Burden
drug daysProtocolized Stage-based InterventionUsual Care
Nephrotoxic Burden1.44 (1.15 to 1.80)1.37 (1.09 to 1.73)
Statistical analysis
  • Protocolized Stage-based Intervention vs Usual Care · Mixed Models Analysis · p = 0.409 · Incidence rate ratio (irr): 1.05 · 95% CI 0.94 to 1.17Negative binomial generalized linear mixed model

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Protocolized Stage-based Intervention———
Usual Care———

Baseline characteristics

There were 698 enrolled physicians but 480 physician participants because physicians were enrolled as members of randomized clusters, but some did not care for any patients who met the automated alert and patient inclusion criterion during the study period, therefore no intervention was delivered, no baseline characteristics are provided and no patient outcome data was included for those physicians.

Age, Continuous
Age, Continuous(years)Protocolized Stage-based InterventionUsual CareTotal
Median43 (36 to 54)45 (39 to 55)44 (37 to 55)
Sex: Female, Male
Sex: Female, Male(Participants)Protocolized Stage-based InterventionUsual CareTotal
Female82109191
Male167119286
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Protocolized Stage-based InterventionUsual CareTotal
Count of participants——0
08

Study locations

8 sites
  • UPMC Altoona
    Altoona, Pennsylvania 16601, United States
  • UPMC Horizon
    Farrell, Pennsylvania 16121, United States
  • UPMC McKeesport
    McKeesport, Pennsylvania 15132, United States
  • UPMC Jameson
    New Castle, Pennsylvania 16105, United States
  • UPMC Magee
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Presbyterian/Montefiore
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Shadyside
    Pittsburgh, Pennsylvania 15232, United States
  • UPMC Williamsport
    Williamsport, Pennsylvania 17701, United States
09

References and documents

Publications

  • Stottlemyer BA, Kellum JA, Bihorac A, Ozrazgat-Baslanti T, Murugan R, Chang CH, Amatullah N, Tran TL, Lukan CJ, Elder MM, Adiyeke E, Ren Y, Ricketts D, Emanuele B, Rashidi P, Kane-Gill SL. Multi-hospital electronic decision support for drug-associated acute kidney injury (MEnD-AKI): Study protocol for a randomized clinical trial. Contemp Clin Trials. 2025 Oct;157:108055. doi: 10.1016/j.cct.2025.108055. Epub 2025 Aug 22. PubMed 40850370 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 17 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 17 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 20, 2024
StartActual
Feb 15, 2024
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 15, 2025
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Eligibility
1 criterion added
What changed in the criteria
  • AddedPatient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Major Adverse Kidney Events within 30 days of randomization (MAKE30)Now Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled PhysiciansTime frame: up to 30 days
Nov 10, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedAKI Intensity: Duration of AKI for all stagesPatients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI stagefor Patients Stage 3Time frame: up to 30 days
  • EditedNephrotoxic burdenBurdenTime frame: up to 30 days
  • ChangedBefore Progression of AKI from time of Level B intervention (first alert generated) to hospital dischargeNow Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital DischargeTime frame: up to 30 days
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Eligibility 1 criterion added
    What changed in the criteria
    • AddedPatient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Major Adverse Kidney Events within 30 days of randomization (MAKE30)Now Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled PhysiciansTime frame: up to 30 days
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedAKI Intensity: Duration of AKI for all stagesPatients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI stagefor Patients Stage 3Time frame: up to 30 days
    • EditedNephrotoxic burdenBurdenTime frame: up to 30 days
    • ChangedBefore Progression of AKI from time of Level B intervention (first alert generated) to hospital dischargeNow Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital DischargeTime frame: up to 30 days
    + 4 other changes: verification date, oversight details, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06264752
Responsible party
Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM (Professor of Pharmacy, Department of Pharmacy and Therapeutics, University of Pittsburgh) — Principal investigator
First posted
Feb 20, 2024
Start date
Feb 15, 2024
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Sandra L Kane-Gill, PharmD, MS
principal investigator · University of Pittsburgh
Azra Bihorac, MD, MS
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion